PharmaShots | Incisive News in 3 Shots

Subscribe Now

Hairy Cell Leukemia

$Innate's Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA's MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemia$

Innate's Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA's MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemi...

January 3, 2020

AstraZeneca's Lumoxiti Receives FDA approval for the Treatment of R/R 2L+ Hairy Cell Leukemia in patients

AstraZeneca's Lumoxiti Receives FDA approval for the Treatment of R/R 2L+ Hairy Cell Leukemia in patients

September 14, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us